These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 26138901)
1. Review: basics of drug development in rheumatology. Mina-Osorio P Arthritis Rheumatol; 2015 Oct; 67(10):2581-90. PubMed ID: 26138901 [No Abstract] [Full Text] [Related]
2. Pharmacogenetics in the rheumatic diseases. Cronstein BN Bull NYU Hosp Jt Dis; 2006; 64(1-2):16-9. PubMed ID: 17121484 [TBL] [Abstract][Full Text] [Related]
4. Pharmacogenomics in pediatric rheumatology. Becker ML Curr Opin Rheumatol; 2012 Sep; 24(5):541-7. PubMed ID: 22732686 [TBL] [Abstract][Full Text] [Related]
5. Methotrexate and long-term treatment of rheumatic disease: comment on the article by Kremer. Ranganathan P; McLeod HL Arthritis Rheum; 2005 Feb; 52(2):670-1; author reply 672. PubMed ID: 15692997 [No Abstract] [Full Text] [Related]
6. Novel immunological targets in rheumatic diseases: clues from current therapies. D'Acquisto F; Rattazzi L; Piras G; Galuppo ML Drug Discov Today; 2014 Aug; 19(8):1155-60. PubMed ID: 24984284 [TBL] [Abstract][Full Text] [Related]
7. [Antimalarial preparations in rheumatology: new prospects]. Nasonov EL Ter Arkh; 1996; 68(1):67-71. PubMed ID: 8644039 [No Abstract] [Full Text] [Related]
8. Pharmacogenetics and rheumatology: Molecular mechanisms contributing to variability in drug response. Asanuma Y; Xie HG; Stein CM Arthritis Rheum; 2005 May; 52(5):1349-59. PubMed ID: 15880820 [No Abstract] [Full Text] [Related]
9. [Tolerance of anti-TNF alpha: the experience acquired in inflammatory rheumatic disease]. Mariette X Ann Dermatol Venereol; 2006 May; 133(5 Pt 2):1S8-12. PubMed ID: 16967603 [No Abstract] [Full Text] [Related]
10. Pharmacology and pharmacokinetics of methotrexate in rheumatic disease. Practical issues in treatment and design. Hillson JL; Furst DE Rheum Dis Clin North Am; 1997 Nov; 23(4):757-78. PubMed ID: 9361154 [TBL] [Abstract][Full Text] [Related]
11. Advances in Targeted Therapies VI. Proceedings of the 6th International Symposium. Venice, Italy, 28 April-2 May 2004. Ann Rheum Dis; 2004 Nov; 63 Suppl 2():ii1-101. PubMed ID: 15479863 [No Abstract] [Full Text] [Related]
13. [Treat-to-target in rheumatology]. Majdan M Wiad Lek; 2015; 68(3):259-64. PubMed ID: 26753210 [TBL] [Abstract][Full Text] [Related]
14. [The use of methotrexate in rheumatology: results and prospects]. Nasonov EL Klin Med (Mosk); 1996; 74(5):10-5. PubMed ID: 8999172 [No Abstract] [Full Text] [Related]
15. Geropharmacology for the rheumatologist. Percy LA; Fang MA Rheum Dis Clin North Am; 2000 Aug; 26(3):433-54, v-vi. PubMed ID: 10989506 [TBL] [Abstract][Full Text] [Related]
16. [Fetal safety profile of drugs used in the treatment of inflammatory rheumatic diseases]. Falcão S; Mourão AF; Pimentão JB; Branco JC Acta Reumatol Port; 2007; 32(4):323-31. PubMed ID: 18159198 [TBL] [Abstract][Full Text] [Related]
17. Do rheumatology cost-effectiveness analyses make sense? Wolfe F; Michaud K; Pincus T Rheumatology (Oxford); 2004 Jan; 43(1):4-6. PubMed ID: 14523227 [No Abstract] [Full Text] [Related]
18. Effectiveness of biologics in rheumatology: improving the evidence base. Silman AJ; Ades AE Rheumatology (Oxford); 2011 Sep; 50 Suppl 4():iv1-2. PubMed ID: 21859699 [No Abstract] [Full Text] [Related]
19. [Evidence based medicine in rheumatology]. Gause A; Raspe HH Z Rheumatol; 2002 Oct; 61(5):516-8. PubMed ID: 12399877 [No Abstract] [Full Text] [Related]
20. Patient based methods for assessing adverse events in clinical trials in rheumatology. Progress report for the OMERACT Drug Toxicity Working Party. Outcome Measures in Rheumatology. Gazarian M; Tugwell P; Boers M; Bombardier C; Brooks P; Day R; Strand V; Wells G J Rheumatol; 1999 Jan; 26(1):207-9. PubMed ID: 9918265 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]